In summary, 5-Aza-2’ and TAK981 have potential to synergistically inhibit tumor cell growth and UBC9 and DNMT1 expression could be potential biomarkers for sensitivity of lymphomas for the combination therapy. Here, UBE2I is linked to neoplasm.